386 related articles for article (PubMed ID: 20631352)
1. A role of the bile salt receptor FXR in atherosclerosis.
Hageman J; Herrema H; Groen AK; Kuipers F
Arterioscler Thromb Vasc Biol; 2010 Aug; 30(8):1519-28. PubMed ID: 20631352
[TBL] [Abstract][Full Text] [Related]
2. Role of bile acids and bile acid receptors in metabolic regulation.
Lefebvre P; Cariou B; Lien F; Kuipers F; Staels B
Physiol Rev; 2009 Jan; 89(1):147-91. PubMed ID: 19126757
[TBL] [Abstract][Full Text] [Related]
3. Bile-acid-activated receptors: targeting TGR5 and farnesoid-X-receptor in lipid and glucose disorders.
Fiorucci S; Mencarelli A; Palladino G; Cipriani S
Trends Pharmacol Sci; 2009 Nov; 30(11):570-80. PubMed ID: 19758712
[TBL] [Abstract][Full Text] [Related]
4. Bile acids induce energy expenditure by promoting intracellular thyroid hormone activation.
Watanabe M; Houten SM; Mataki C; Christoffolete MA; Kim BW; Sato H; Messaddeq N; Harney JW; Ezaki O; Kodama T; Schoonjans K; Bianco AC; Auwerx J
Nature; 2006 Jan; 439(7075):484-9. PubMed ID: 16400329
[TBL] [Abstract][Full Text] [Related]
5. Bile acid-activated receptors in the treatment of dyslipidemia and related disorders.
Fiorucci S; Cipriani S; Baldelli F; Mencarelli A
Prog Lipid Res; 2010 Apr; 49(2):171-85. PubMed ID: 19932133
[TBL] [Abstract][Full Text] [Related]
6. Bile acids and signal transduction: role in glucose homeostasis.
Nguyen A; Bouscarel B
Cell Signal; 2008 Dec; 20(12):2180-97. PubMed ID: 18634871
[TBL] [Abstract][Full Text] [Related]
7. Nuclear bile acid receptor FXR as pharmacological target: are we there yet?
Modica S; Moschetta A
FEBS Lett; 2006 Oct; 580(23):5492-9. PubMed ID: 16904670
[TBL] [Abstract][Full Text] [Related]
8. The role of bile salts in liver regeneration.
van de Laarschot LF; Jansen PL; Schaap FG; Olde Damink SW
Hepatol Int; 2016 Sep; 10(5):733-40. PubMed ID: 27048617
[TBL] [Abstract][Full Text] [Related]
9. The Farnesoid X receptor: a molecular link between bile acid and lipid and glucose metabolism.
Claudel T; Staels B; Kuipers F
Arterioscler Thromb Vasc Biol; 2005 Oct; 25(10):2020-30. PubMed ID: 16037564
[TBL] [Abstract][Full Text] [Related]
10. FXR an emerging therapeutic target for the treatment of atherosclerosis.
Mencarelli A; Fiorucci S
J Cell Mol Med; 2010 Jan; 14(1-2):79-92. PubMed ID: 20041971
[TBL] [Abstract][Full Text] [Related]
11. FXR: a promising target for the metabolic syndrome?
Cariou B; Staels B
Trends Pharmacol Sci; 2007 May; 28(5):236-43. PubMed ID: 17412431
[TBL] [Abstract][Full Text] [Related]
12. Dual activation of the bile acid nuclear receptor FXR and G-protein-coupled receptor TGR5 protects mice against atherosclerosis.
Miyazaki-Anzai S; Masuda M; Levi M; Keenan AL; Miyazaki M
PLoS One; 2014; 9(9):e108270. PubMed ID: 25237811
[TBL] [Abstract][Full Text] [Related]
13. Nuclear receptors in cholesterol catabolism: molecular biology of the enterohepatic circulation of bile salts and its role in cholesterol homeostasis.
Redinger RN
J Lab Clin Med; 2003 Jul; 142(1):7-20. PubMed ID: 12878981
[TBL] [Abstract][Full Text] [Related]
14. Intestine farnesoid X receptor agonist and the gut microbiota activate G-protein bile acid receptor-1 signaling to improve metabolism.
Pathak P; Xie C; Nichols RG; Ferrell JM; Boehme S; Krausz KW; Patterson AD; Gonzalez FJ; Chiang JYL
Hepatology; 2018 Oct; 68(4):1574-1588. PubMed ID: 29486523
[TBL] [Abstract][Full Text] [Related]
15. Bile acids, farnesoid X receptor, atherosclerosis and metabolic control.
Kuipers F; Stroeve JH; Caron S; Staels B
Curr Opin Lipidol; 2007 Jun; 18(3):289-97. PubMed ID: 17495603
[TBL] [Abstract][Full Text] [Related]
16. Bile acids as regulators of hepatic lipid and glucose metabolism.
Trauner M; Claudel T; Fickert P; Moustafa T; Wagner M
Dig Dis; 2010; 28(1):220-4. PubMed ID: 20460915
[TBL] [Abstract][Full Text] [Related]
17. Farnesoid X receptor: from medicinal chemistry to clinical applications.
Fiorucci S; Mencarelli A; Distrutti E; Zampella A
Future Med Chem; 2012 May; 4(7):877-91. PubMed ID: 22571613
[TBL] [Abstract][Full Text] [Related]
18. Bile Acid Control of Metabolism and Inflammation in Obesity, Type 2 Diabetes, Dyslipidemia, and Nonalcoholic Fatty Liver Disease.
Chávez-Talavera O; Tailleux A; Lefebvre P; Staels B
Gastroenterology; 2017 May; 152(7):1679-1694.e3. PubMed ID: 28214524
[TBL] [Abstract][Full Text] [Related]
19. FXR deficiency causes reduced atherosclerosis in Ldlr-/- mice.
Zhang Y; Wang X; Vales C; Lee FY; Lee H; Lusis AJ; Edwards PA
Arterioscler Thromb Vasc Biol; 2006 Oct; 26(10):2316-21. PubMed ID: 16825595
[TBL] [Abstract][Full Text] [Related]
20. Hypoxia downregulates farnesoid X receptor via a hypoxia-inducible factor-independent but p38 mitogen-activated protein kinase-dependent pathway.
Fujino T; Murakami K; Ozawa I; Minegishi Y; Kashimura R; Akita T; Saitou S; Atsumi T; Sato T; Ando K; Hara S; Kikugawa K; Hayakawa M
FEBS J; 2009 Mar; 276(5):1319-32. PubMed ID: 19187229
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
